These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15529021)

  • 1. Role of CETP inhibitors in the treatment of dyslipidemia.
    van der Steeg WA; Kuivenhoven JA; Klerkx AH; Boekholdt SM; Hovingh GK; Kastelein JJ
    Curr Opin Lipidol; 2004 Dec; 15(6):631-6. PubMed ID: 15529021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
    Van der Steeg WA; El-Harchaoui K; Kuivenhoven JA; Kastelein JJ
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):481-8. PubMed ID: 16503868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
    de Grooth GJ; Kuivenhoven JA; Stalenhoef AF; de Graaf J; Zwinderman AH; Posma JL; van Tol A; Kastelein JJ
    Circulation; 2002 May; 105(18):2159-65. PubMed ID: 11994249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Curr Opin Lipidol; 2006 Aug; 17(4):394-8. PubMed ID: 16832162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
    Kuivenhoven JA; de Grooth GJ; Kawamura H; Klerkx AH; Wilhelm F; Trip MD; Kastelein JJ
    Am J Cardiol; 2005 May; 95(9):1085-8. PubMed ID: 15842977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
    Athyros VG; Kakafika A; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Investig Drugs; 2008 Apr; 17(4):445-9. PubMed ID: 18363511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JTT-705: is there still future for a CETP inhibitor after torcetrapib?
    Rennings AJ; Stalenhoef A
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The end of the road for CETP inhibitors after torcetrapib?
    Joy T; Hegele RA
    Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1365-8. PubMed ID: 15461565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H; Yonemori F; Wakitani K; Minowa T; Maeda K; Shinkai H
    Nature; 2000 Jul; 406(6792):203-7. PubMed ID: 10910363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.
    Kolovou GD; Anagnostopoulou KK; Kostakou PM; Mikhailidis DP
    Curr Med Chem; 2009; 16(33):4345-60. PubMed ID: 19835569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
    Barter PJ; Brewer HB; Chapman MJ; Hennekens CH; Rader DJ; Tall AR
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):160-7. PubMed ID: 12588754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.